[{"id":"34339220-1770-4108-8649-484d7d43cefa","acronym":"212-Pb-VMT","url":"https://clinicaltrials.gov/study/NCT05636618","created_at":"2022-12-05T15:56:36.062Z","updated_at":"2025-02-25T17:38:15.153Z","phase":"Phase 1/2","brief_title":"Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors","source_id_and_acronym":"NCT05636618 - 212-Pb-VMT","lead_sponsor":"Perspective Therapeutics","biomarkers":" SSTR • CD4 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR • CD4 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMT-𝛼-NET"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/27/2023","start_date":" 09/27/2023","primary_txt":" Primary completion: 11/26/2029","primary_completion_date":" 11/26/2029","study_txt":" Completion: 12/26/2029","study_completion_date":" 12/26/2029","last_update_posted":"2025-01-29"},{"id":"e6ad9910-26f5-478f-813c-389648b33623","acronym":"SCARLET","url":"https://clinicaltrials.gov/study/NCT04379817","created_at":"2021-02-11T16:55:05.338Z","updated_at":"2024-07-02T16:35:12.200Z","phase":"Phase 2","brief_title":"Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients","source_id_and_acronym":"NCT04379817 - SCARLET","lead_sponsor":"Jules Bordet Institute","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR Expression • SSTR2 positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression • SSTR2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/25/2020","start_date":" 02/25/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-03-29"},{"id":"4401c394-5d2d-4472-8e80-7bc5059b71df","acronym":"LUFOR","url":"https://clinicaltrials.gov/study/NCT06045260","created_at":"2023-09-21T15:10:50.581Z","updated_at":"2024-07-02T16:35:36.405Z","phase":"Phase 2","brief_title":"\"Receptor Radionuclide Therapy With 177Lu-DOTATOC","source_id_and_acronym":"NCT06045260 - LUFOR","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-09-21"},{"id":"996bba9a-762c-4c0d-a3e9-1b3284ea0005","acronym":"","url":"https://clinicaltrials.gov/study/NCT03044977","created_at":"2021-02-11T16:53:19.964Z","updated_at":"2024-07-02T16:35:39.819Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors","source_id_and_acronym":"NCT03044977","lead_sponsor":"David Bushnell","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive • SSTR2 positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/07/2017","start_date":" 05/07/2017","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-08-16"},{"id":"0d0d15de-eb4a-4e35-9e1e-388c588b5f9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03971461","created_at":"2021-01-18T19:32:12.909Z","updated_at":"2024-07-02T16:35:40.851Z","phase":"Phase 2","brief_title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","source_id_and_acronym":"NCT03971461","lead_sponsor":"NYU Langone Health","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-08-04"},{"id":"a8d3d321-676b-43b3-809c-1d0358c715d7","acronym":"PEN-221-001","url":"https://clinicaltrials.gov/study/NCT02936323","created_at":"2021-02-11T16:53:16.188Z","updated_at":"2024-07-02T16:36:19.555Z","phase":"Phase 1/2","brief_title":"PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers","source_id_and_acronym":"NCT02936323 - PEN-221-001","lead_sponsor":"Tarveda Therapeutics","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive • SSTR2 positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nendratareotide uzatansine (PEN-221)"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 12/08/2016","start_date":" 12/08/2016","primary_txt":" Primary completion: 07/31/2020","primary_completion_date":" 07/31/2020","study_txt":" Completion: 02/25/2021","study_completion_date":" 02/25/2021","last_update_posted":"2021-12-14"},{"id":"b1b04648-20c2-4a90-911c-dd343338ffcd","acronym":"LUTHREE","url":"https://clinicaltrials.gov/study/NCT03454763","created_at":"2021-03-16T19:52:39.487Z","updated_at":"2024-07-02T16:36:45.770Z","phase":"Phase 2","brief_title":"Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors","source_id_and_acronym":"NCT03454763 - LUTHREE","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Unknown status","enrollment":" Enrollment 618","initiation":"Initiation: 05/26/2016","start_date":" 05/26/2016","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2020-04-21"}]